
We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.
Current Opportunities
Director of Clinical Quality Assurance
89bio Inc
89bio Inc
San Francisco, CA
Posted: 08 Dec 2020Closes: 06 Jun 2021 15:55
Posted: 08 Dec 2020Closes: 06 Jun 2021 15:55
Senior Director Medical Writing
89 Bio Inc
89 Bio Inc
San Francisco, CA
Posted: 11 Nov 2020Closes: 10 May 2021 21:17
Posted: 11 Nov 2020Closes: 10 May 2021 21:17
Accounts Payable Supervisor
89 Bio Inc
89 Bio Inc
San Francisco, CA
Posted: 11 Nov 2020Closes: 10 May 2021 21:07
Posted: 11 Nov 2020Closes: 10 May 2021 21:07
Clinical Research Associate (CRA)
89bio Inc
89bio Inc
San Francisco, CA
Posted: 25 Oct 2020Closes: 23 Apr 2021 07:14
Posted: 25 Oct 2020Closes: 23 Apr 2021 07:14